CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 323 enrolled
Drug / intervention
Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04490057
NCT04490057Phase 4Completed
CompareCT.gov

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

Yale University·interventional·Posted Jul 28, 2020·Updated Jan 5, 2026

In Brief

A Phase 4 clinical trial evaluating Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler, Varenicline or bupropion, and 1 other intervention for Tobacco Use Cessation. Completed, enrolled 323 participants across 4 sites.

Detailed Summary

Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated. This study plans to assess the ability of various clinical pathways involving tobacco treatment medications and contingency management (paying smokers for not smoking) to improve smoking cessation in a group of PLWH.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Cessation
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJul 28, 2020
Enrollment StartJul 27, 2020
Primary CompletionOct 24, 2024
Study CompletionOct 24, 2025
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 5.9 years ago

Interventions

Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhalerdrug

Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.

Varenicline or bupropiondrug

Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).

Contingency Managementbehavioral

Participants will be financially rewarded for abstinence to tobacco.